Journals / Çocuk Sağlığı ve Hastalıkları Dergisi / 1997 / Cilt: 40 - Sayı: 3

The effect of inhaled budesonide on bronchial hyperreactivity in children with bronchial asthma

İnhale budesonid'in bronşial astmalı çocuklarda bronş hiperreaktivitesine etkisi

Pages
351–360
Publication Date
2022-10-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Our results suggest that antiinflammatory treatment can modulate BHR's severity, and that bronchial inflammation plays a role in the pathogenesis of BHR.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The effect of an inhaled corticosteroid, budesonide, on bronchial hyperreactivity (BHR) was investigated in 24 children with moderate asthma through a double-blind, placebo-controlled parallel group trial.
📊
Key Findings & Data:Patients were evaluated for FEV1; methacholine concentration which causes a 20 percent decrease in FEV1 (PC20); and morning and evening peak expiratory flows, symptoms scores, and bronchodilator requirements.
💡
Conclusion & Impact:Our results suggest that antiinflammatory treatment can modulate BHR's severity, and that bronchial inflammation plays a role in the pathogenesis of BHR.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

The effect of an inhaled corticosteroid, budesonide, on bronchial hyperreactivity (BHR) was investigated in 24 children with moderate asthma through a double-blind, placebo-controlled parallel group trial. Following a two-week baseline period, patients were randomized into two groups to receive one of the treatments for a period of eight weeks. Patients were evaluated for FEV1; methacholine concentration which causes a 20 percent decrease in FEV1 (PC20); and morning and evening peak expiratory flows, symptoms scores, and bronchodilator requirements. Four weeks of budesonide treatment improved symptom scores, bronchodilator requirements and PEF rates, whereas FEV1 and PC20 methacholine improved after eight weeks of treatment. Our results suggest that antiinflammatory treatment can modulate BHR's severity, and that bronchial inflammation plays a role in the pathogenesis of BHR.

Özet

Bir inhale kortikoşteroid olan budesonidin bronş hiperreaktivitesine (BHR) etkisi, 24 orta şiddette âstmalı çocuk hastada çift kör, plasebo kontrollü paralel bir çalışma ile araştırıldı. İki haftalık ön izlem döneminin ardından rastgele iki gruba ayrılan hastaların sekiz hafta süre ile plasebo veya budesonid tedavisinden birini almaları sağlandı. Hastalar birinci saniyedeki zorlu ekspiratuvar hacimde (FEV1) %20'lik azalmaya neden olan metakolin konsantrasyonu (PC20), FEV1, sabah ve akşam ölçülen ekspiratuvar zirve akım hızları, semptom skorları ve bronkodilatör gereksinimleri yönünden değerlendirildiler. Budesonid tedavisi ile semptom skorlarında, bronkodilatör gereksiniminde ve ekspiratuvar zirve akım hızlarında dördüncü haftada düzelme saptanırken, FEV1 ve PC20'de düzelme ancak sekiz haftalık tedavinin sonunda saptandı. Bu çalışma anti-enflamatuvar ilaçlarla ile BHR şiddetinin azaltılabileceği sonucuna varıldı ve BHR patogenezinde bronşial inflamasyonun rolü bir kez daha desteklendi.

🔖

Cite This Article

TUNCER, A., SARAÇLAR, Y., ADALIOĞLU, G., ŞEKEREL, B. E. (2022). The effect of inhaled budesonide on bronchial hyperreactivity in children with bronchial asthma. Çocuk Sağlığı ve Hastalıkları Dergisi, Cilt: 40 - Sayı: 3, 351–360. https://ajindex.com/articles/484319